Search Follow us


1 - 12 of 22
Sort by: popularity | newest
Page  2  of 2 | Next
Quantum Genomics

Strong Phase IIb data in hypertension

Update | Pharmaceutical & healthcare | 13 Nov 2018

Quantum Genomics released data from the Phase IIb NEW-HOPE trial, which strongly suggests that firibistat is an efficacious, safe drug with a differentiated mechanism that will address a very large patient population. After eight weeks of treatment, patients saw a statistically significant reduction from baseline (p<0.0001) in systolic automated office blood pressure (AOBP) of 9.7mmHg. Importantly there was no oedema that was seen with some of the other major classes of hypertension treatments.

Nanoco Group

Executive interview – Nanoco Group

Edison TV: | Technology | 19 Oct 2018

In this interview Nanoco's CEO Michael Edelman discusses progress with the company's key US nanomaterials partner as it moves towards larger production volumes, expected for H1 FY20. He talks about the company's IP portfolio and why increased patent-filing activity could signal that the time for quantum dots may now have come. He also discusses the display market and what needs to happen to drive broader adoption of quantum dot televisions. New CFO, Brian Tenner, discusses why he joined the business, guidance for FY19 and what the financial profile of the business might look like once volume shipments commence.

Quantum Genomics

NEW-HOPE data to be presented at AHA

Update | Pharmaceutical & healthcare | 09 Oct 2018

Quantum Genomics has announced that the results of its Phase IIb NEW-HOPE study will be presented in a late-breaking presentation at the American Heart Association (AHA) annual meeting on 10 November 2018. Late-breaking presentations are typically reserved for results that are of high interest or impact and this presentation will help increase the profile of both Quantum Genomics and firibastat with physicians, potential partners and investors. We view it as positive that the trial enrolled much faster than expected and that the results will be presented at AHA in a late-breaking presentation.

Quantum Genomics

NEW-HOPE enrolled much faster than expected

Update | Pharmaceutical & healthcare | 10 Sep 2018

Quantum Genomics announced that it has enrolled the NEW-HOPE trial faster than expected, with data to come around mid-November (previously around the end of Q119). In our opinion, the faster enrolment rate is positive as this is an open-label trial and hence we suspect that results seen by physicians to date are encouraging. As a reminder, NEW-HOPE is a study of firibastat in 256 hypertensive overweight patients across 25 major US hospitals, with a primary endpoint of change from baseline in office systolic blood pressure (SBP) at week eight.

Quantum Genomics

A little company going after big indications

Outlook | Pharmaceutical & healthcare | 13 Jul 2018

Quantum Genomics is a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. Its lead programme, firibastat (QGC001), is in a 250-patient Phase IIb study in hypertensive overweight patients with patient dosing expected to be completed by the end of 2018 and data in Q119. Another Phase IIb in 300 subjects enrolled within 24 hours after suffering acute myocardial infarction (AMI) is expected to launch by the end of 2018 with results due in H220.

Quantum Genomics

The QUORUM trial

Update | Pharmaceutical & healthcare | 28 Jun 2018

In April, Quantum Genomics announced it would be moving forward with the Phase IIb trial in heart failure and has recently announced the design of this study. The QUORUM study will assess the safety and efficacy of Quantum’s drug firibastat (QGC001) compared to ramipril (brand name Altace), an angiotensin-converting-enzyme (ACE) inhibitor, in 300 subjects enrolled within 24 hours after suffering acute myocardial infarction (AMI). The study is expected to launch by the end of 2018 with results due in H220.

Quantum Genomics

Accelerating timelines

Update | Pharmaceutical & healthcare | 23 Apr 2018

Quantum Genomics made a number of announcements when it presented its three-year strategic plan on 19 April 2018. Importantly, it is accelerating both its hypertension and heart failure programmes. The NEW-HOPE study in 250 hypertensive overweight patients is expected to complete patient dosing by the end of the year (previously Q119). It is also moving forward with the Phase IIb trial in heart failure without waiting for the final results due to the safety data seen so far and positive results in recent animal studies. The study is expected to launch in Q418 with results expected in H220.

Quantum Genomics

NEW-HOPE trial recruiting rapidly

Update | Pharmaceutical & healthcare | 04 Apr 2018

Quantum Genomics recently announced its 2017 results and updated the status of its NEW-HOPE study in 250 hypertensive overweight patients across 25 major hospitals in the US. According to the company, the study’s recruitment has been very rapid and exceeded initial projections. Final data are expected in H119. In the near term, the company is expected to announce a three-year strategic plan on 19 April.

Nanoco Group

Executive interview - Nanoco Group

Edison TV: | Technology | 20 Nov 2017

CEO of Nanoco, Dr Michael Edelman, discusses the operational highlights of the last year, which included the first commercial orders for the company’s cadmium free quantum dots in computer displays. He explains why the commercialisation cycle has been more protracted than initially thought but expresses confidence that the company now has a healthy pipeline of potential customers moving closer towards commercial orders. Michael also provides an update on the company’s competitive positioning, and the developments of the technology for non-display applications. Finally, Michael talks about the milestones that investors should be looking for in 2018.

Quantum Genomics

NEW-HOPE trial launched

Update | Pharmaceutical & healthcare | 05 Oct 2017

Quantum Genomics recently announced H117 financial results and gave a business update for the first three quarters of the year. It highlighted the results of its Phase IIa trial for QGC001 in hypertension and the launch of the NEW-HOPE study in 250 hypertensive overweight patients across 25 major hospitals in the United States. The company is expecting to complete its 75-patient Phase II study of QGC001 in heart failure by the end of the year, with data expected in H118.

Nanoco Group

Cadmium to be prohibited from October 2019

Flash note | Technology | 09 Aug 2017

Proposed amendments (subject to ratification) to the Restriction of Hazardous Substances Directive (RoHS) by the European Commission recommend a two-year more restrictive extension to the exemption of cadmium in quantum dot displays, subsequent to which the use of any cadmium in electronic devices sold within the EU will be banned. The use of cadmium in lighting products will be prohibited with immediate effect. The judgement has little impact on our investment thesis, as we believe that commercial factors for cadmium-free adoption are already strong.

Nanoco Group

First commercial orders

Update | Technology | 30 Jun 2017

The receipt of first orders from Wah Hong was an important step forward. Just as importantly, the CFQD product is now being evaluated by 13 major OEMs for 16 programmes, giving confidence that revenues are now set to ramp up, as more programmes progress through the pipeline and shipment volumes increase. We also note that the exit of 3M, one of (Nanoco competitor) Nanosys's film partners should be helpful. A £485k grant for Nanoco from Innovate UK to develop quantum dots for the detection of Pancreatic cancer reminds us that there is more to the company than just display - other non-display applications include lighting and solar power generation. Nevertheless in the near term, the investment case will hinge around progress in display.